Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Completed1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

completed150%
enrolling_by_invitation150%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitationphase_2

Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients

NCT07375693
completedphase_1

Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders

NCT03514732

Clinical Trials (2)

Showing 2 of 2 trials
NCT07375693Phase 2

Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients

Enrolling By Invitation
NCT03514732Phase 1

Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2